Please assess the completion status of the following clinical trial:

Trial Title: Early Parkinson's Disease (PD) Cross-Sectional

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. 35-80 year old men \& women~2. Patients with iPD or Parkinsonian syndromes, or controls consisting of healthy subjects, or subjects who have a non-neurodegenerative diagnosis but are otherwise healthy.~3. Gives written informed consent~4. Pregnant women are not excluded, but will be identified by HCG.~Exclusion Criteria:~1. Parkinsonian symptoms not due to idiopathic (sporadic) PD, such as those that are medication induced, toxic substance induced or representative of an atypical Parkinsonian syndrome will be categorized separately.~2. Any unstable or uncontrolled medical or psychiatric condition.~3. Renal (creatinine over 1.6) or hepatic insufficiency (LFT three-fold higher than normal range), or a history of significant cardiac disease.~4. If there is a history or evidence of coagulopathy, on medications such as Plavix, Aggrenox, heparin, coumadin, or large doses of aspirin, must be able to remain off these medications for at least 3 days, and have stable blood coagulation values prior to any lumbar puncture (LP).~5. Significant dementia (MMSE\<25/30 or MOCA\<25/30) that would interfere with study procedures or the giving of informed consent for the study .~6. Active infections including skin, respiratory or GI infections, and HIV+ (if undergoing an LP).~7. Any evidence of a different neurodegenerative disorder, for example, Alzheimer's Disease or Huntington's Disease.~8. fMRI will not be performed is screening questionnaire identifies a reason.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Clinically diagnosed Early iPD
- 2 (Type: None): Age/gender matched controls without neurodegenerative diagnosis
- atypical or late Parkinsonian Syndromes (Type: None): Includes subjects facing or having undergone DBS, diagnoses of MSA, PSP or other atypical syndromes.

Based on this trial design, predict the completion outcome and termination type (if applicable).